Literature DB >> 31359658

[Efficacy and mechanism of Lianhua Qingwen Capsules(LHQW) on chemotaxis of macrophages in acute lung injury (ALI) animal model].

Qi Li1, Jie Yin2, Qing-Sen Ran1, Qing Yang1, Li Liu1, Zheng Zhao1, Yu-Jie Li1, Ying Chen1, Li-Dong Sun1, Ya-Jie Wang1, Xiao-Gang Weng1, Wei-Yan Cai1, Xiao-Xin Zhu1.   

Abstract

This paper was mainly to discuss the potential role and mechanism of Lianhua Qingwen Capsules(LHQW) in inhibiting pathological inflammation in the model of acute lung injury caused by bacterial infection. For in vitro study, the mRNA expression of MCP-1 in RAW264.7 cells and THP-1 cells, the content of MCP-1 in cell supernatant, as well as the effect of LHQW on chemotaxis of macrophages were detected. For in vivo study, mice were randomly divided into 7 groups, including normal group, model group(LPS 5 mg·kg~(-1)), LHQW 300, 600 and 1 200 mg·kg~(-1)(low, middle and high dose) groups, dexamethasone 5 mg·kg~(-1) group and penicillin-streptomycin group. Then, the anal temperature was detected two hours later. Dry weight and wet weight of lung tissues in mice were determined; TNF-α and MCP-1 levels in alveolar lavage fluid and MCP-1 in serum were detected. In addition, the infiltration of alveolar macrophages was also observed and the infiltration count of alveolar macrophages was measured by CCK-8 method. HE staining was also used to observe the inflammatory infiltration of lung tissues in mice. Both of the in vitro and in vivo data consistently have confirmed that: by down-regulating the expression of MCP-1, LHWQ could efficiently decrease the chemotaxis of monocytes toward the pulmonary infection foci, thus blocking the disease development in ALI animal model.

Entities:  

Keywords:  Lianhua Qingwen Capsules; MCP-1; acute lung injury; macrophage

Mesh:

Substances:

Year:  2019        PMID: 31359658     DOI: 10.19540/j.cnki.cjcmm.20190210.001

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  7 in total

Review 1.  Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.

Authors:  Yu-Qiong He; Can-Can Zhou; Lu-Yao Yu; Liang Wang; Jiu-Ling Deng; Yu-Long Tao; Feng Zhang; Wan-Sheng Chen
Journal:  Pharmacol Res       Date:  2020-09-29       Impact factor: 7.658

2.  Establishment of an anti-inflammation-based bioassay for the quality control of the 13-component TCM formula (Lianhua Qingwen).

Authors:  Shuaishuai Chen; Xiaojuan Yang; Ziying Wei; Yanru Zhang; Ying Huang; Zhuo Shi; Ziteng Zhang; Jiabo Wang; Haizhu Zhang; Jianli Ma; Xiaohe Xiao; Ming Niu
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 3.  Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community.

Authors:  Zichao Luo; Melgious Jin Yan Ang; Siew Yin Chan; Zhigao Yi; Yi Yiing Goh; Shuangqian Yan; Jun Tao; Kai Liu; Xiaosong Li; Hongjie Zhang; Wei Huang; Xiaogang Liu
Journal:  Research (Wash D C)       Date:  2020-06-16

4.  Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.

Authors:  Xiaofei Chen; Yunlong Wu; Chun Chen; Yanqiu Gu; Chunyan Zhu; Suping Wang; Jiayun Chen; Lei Zhang; Lei Lv; Guoqing Zhang; Yongfang Yuan; Yifeng Chai; Mingshe Zhu; Caisheng Wu
Journal:  Acta Pharm Sin B       Date:  2020-10-10       Impact factor: 11.413

Review 5.  Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.

Authors:  Wei Zhuang; Zheng Fan; Yanqi Chu; Haizheng Wang; Ying Yang; Li Wu; Nan Sun; Ge Sun; Yuqiao Shen; Xiaolan Lin; Guiming Guo; Shengyan Xi
Journal:  Front Pharmacol       Date:  2020-07-17       Impact factor: 5.810

Review 6.  Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects.

Authors:  Liu-Cheng Li; Zhi-Hui Zhang; Wen-Cheng Zhou; Jie Chen; Hua-Qian Jin; Hong-Mei Fang; Qin Chen; Ye-Cheng Jin; Jiao Qu; Lian-Di Kan
Journal:  Biomed Pharmacother       Date:  2020-08-19       Impact factor: 6.529

Review 7.  Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review.

Authors:  Zhi-Hua Yang; Bin Wang; Qian Ma; Lin Wang; Ya-Xin Lin; Hai-Feng Yan; Zi-Xuan Fan; Hao-Jia Chen; Zhao Ge; Feng Zhu; Hui-Jie Wang; Bao-Nan Zhang; Hai-Dong Sun; Li-Min Feng
Journal:  Front Pharmacol       Date:  2021-07-15       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.